Renalase, a catecholamine-metabolizing hormone from the kidney.

Medical Faculty of the Charite, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Max Delbruck Center for Molecular Medicine, Berlin, Germany.
Cell Metabolism (Impact Factor: 16.75). 07/2005; 1(6):358-60. DOI: 10.1016/j.cmet.2005.05.008
Source: PubMed

ABSTRACT A novel flavin adenine dinucleotide-dependent amine oxidase that is secreted by the kidney, circulates in the blood, and modulates cardiac function and systemic blood pressure has recently been discovered. Renalase appears to be a hormone that metabolizes catecholamines, and its discovery will facilitate our understanding of sympathetic regulation.

1 Bookmark
  • Source
    Advances in Chronic Kidney Disease. 01/2015;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The function of the autonomic nervous system is based on reciprocal interaction between the sympathetic and parasympathetic parts, most frequently in the form of antagonistic action on target organs. The main mediators of the sympathetic nervous system in the effectors part are catecholamines (CA), which are involved in various physiological processes. Moreover, CA also has a profound effect on the kidneys, being factors that impact on renal haemodynamics, and have been reported to be altered in pathological disorders, e.g. extracellular volume expression, hypertension and cardiovascular complications. The increased sympathetic nerve activity, at least in part, can explain the raised in plasma CA observed in chronic kidney diseases. Furthermore, plasma CA levels in ureamic patients cannot be considered a reliable index of sympathetic activity, due to existence of many factors which may affect their values. In addition, CA released into the circulation, as one of many substances, may penetrate across the cellular membranes of erytrocytes (RBC). Taking these observations together, the aim of the presented study was to investigate for the first time the plasma and erythrocyte relationship of catecholamines in haemodialysis. The studies were performed among 37 haemodialysed patients who were inhabitants of the Lublin commune. Plasma and intracellular concentration of CA were measured prior to and following haemodialysis by high performance liquid chromatography with electrochemical detection. The results suggest that RBC are able to accumulate CA at the stage of terminal renal failure; in addition, the levels of adrenaline and dopamine in RBC depend on the accumulation of urea in plasma. It was also found that the dynamic changes in concentration of RBC adrenaline are an independent predictor of mortality in haemodialysis patients.
    Annals of agricultural and environmental medicine: AAEM 09/2014; 21(3):562-6. · 3.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of CKD has increased considerably over the past 2 decades. The rising rates of CKD have been attributed to known comorbidities such as diabetes, hypertension, and obesity; however, recent research has begun to explore the degree to which social, economic, and psychological factors have implications for the prevalence and progression of CKD, especially among high-risk populations such as African Americans. It has been suggested that stress can have implications for CKD, but this area of research has been largely unexplored. One contributing factor associated with the paucity of research on CKD is that many of the social, psychological, and environmental stressors cannot be recreated or simulated in a laboratory setting. Social science has established that stress can have implications for health, and we believe that stress is an important determinant of the development and progression of CKD. We draw heavily from the social scientific and social epidemiologic literature to present an intersectional conceptual frame specifying how stress can have implications for kidney disease, its progression, and its complications through multiple stressors and pathways. C KD is fast becoming a global health problem. The prevalence of CKD remains high, whereas the inci-dence of ESRD or kidney failure continues to increase. 1 If current trends continue, the global implications will be immense because the social and financial costs of care for ESRD patients are considerable. Current esti-mates for the United States indicate that the cost of ESRD exceeded $42 billion in 2009, more than doubling the cost in 2000. 2 These trends indicate that kidney dis-ease represents a serious threat to the world's physical and financial health. Results from a recent study reports that nearly 6 of every 10 Americans will experience moderate kidney disease in their lifetime 3 ; however, the burden of kidney disease is not distributed equally across the population. 4-7 The prevalence of ESRD for African Americans, for example, quadruples the corresponding prevalence for whites. 2,8,9
    Advances in chronic kidney disease. 01/2015; 22(1).


1 Download
Available from